Literature DB >> 14532718

[Inhibitory effect of angiotensin II receptor antagonist on the contraction and growth of hepatic stellate cells].

Soon Koo Baik1, Ho Sung Jo, Ki Tae Suk, Jung Min Kim, Byong Jun Lee, Yeun Jong Choi, Hyun Soo Kim, Dong Ki Lee, Sang Ok Kwon, Keon Il Lee, Seung Kyu Cha, Kyu Sang Park, In Deok Kong.   

Abstract

BACKGROUND/AIMS: This study aimed to investigate the effects of angiotensin II (ANG II) and its receptor antagonist (losartan) on the contraction and growth of HSCs.
METHODS: HSCs were isolated from Sprague Dawley rat and cultured at various conditions as follows: control, pretreatment of 10(-5) M ANG II, pretreatment of 10(-5) M endothelin, and pretreatment of 10(-5) M ANG II and 10(-6) M losartan. We conducted morphologic analysis with cellular area and length by image analysis system to estimate cell growth in each group. In addition, we measured the change of intracellular calcium currents via electrophysiological methods to evaluate the contractile effect of ANG II and losartan on HSCs.
RESULTS: At the fifth day of incubation, the mean cellular area of ANG II-pretreated group and ANG II with losartan-pretreated group were 704.68+/-22.6 micro m2 and 332.90+/-32.6 micro m2, respectively. This difference was statistically significant (p<0.05). ANG II induced an increase in the intracellular calcium current by 22.0+/-3.0% compared with basal current level (p<0.05). However, when losartan was pretreated, ANG II did not cause a significant increase in calcium current (3.1+/-0.8%, p>0.05).
CONCLUSION: ANG II accelerates the contraction and growth of HSCs, while its receptor blocker, losartan, inhibits the contraction and growth of HSCs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14532718

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  6 in total

1.  Switching-on of serotonergic calcium signaling in activated hepatic stellate cells.

Authors:  Kyu-Sang Park; Pyo-Jin Sin; Dong Hyeon Lee; Seung-Kuy Cha; Min-Jeong Kim; Na-Hyun Kim; Soon-Koo Baik; Seong-Woo Jeong; In Deok Kong
Journal:  World J Gastroenterol       Date:  2011-01-14       Impact factor: 5.742

Review 2.  Cardio-oncology Related to Heart Failure: Common Risk Factors Between Cancer and Cardiovascular Disease.

Authors:  Anne Blaes; Anna Prizment; Ryan J Koene; Suma Konety
Journal:  Heart Fail Clin       Date:  2017-04       Impact factor: 3.179

3.  Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence.

Authors:  T Ohyama; K Sato; K Kishimoto; Y Yamazaki; N Horiguchi; T Ichikawa; S Kakizaki; H Takagi; T Izumi; M Mori
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

4.  Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model.

Authors:  Moon Young Kim; Soon Koo Baik; Dong Hun Park; Yoon Ok Jang; Ki Tae Suk; Chang Jin Yea; Il Young Lee; Jae Woo Kim; Hyun Soo Kim; Sang Ok Kwon; Mi Yun Cho; Sang Baik Ko; Sei Jin Chang; Soon Ho Um; Kwang-Hyub Han
Journal:  J Gastroenterol       Date:  2008-11-18       Impact factor: 7.527

5.  Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis.

Authors:  Eugen Florin Georgescu; Reanina Ionescu; Mihaela Niculescu; Laurentiu Mogoanta; Liliana Vancica
Journal:  World J Gastroenterol       Date:  2009-02-28       Impact factor: 5.742

Review 6.  Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension.

Authors:  Kwang Yong Shim; Young Woo Eom; Moon Young Kim; Seong Hee Kang; Soon Koo Baik
Journal:  Korean J Intern Med       Date:  2018-02-21       Impact factor: 2.884

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.